ZA200104533B - Methotrexate derivatives. - Google Patents
Methotrexate derivatives. Download PDFInfo
- Publication number
- ZA200104533B ZA200104533B ZA200104533A ZA200104533A ZA200104533B ZA 200104533 B ZA200104533 B ZA 200104533B ZA 200104533 A ZA200104533 A ZA 200104533A ZA 200104533 A ZA200104533 A ZA 200104533A ZA 200104533 B ZA200104533 B ZA 200104533B
- Authority
- ZA
- South Africa
- Prior art keywords
- mtx
- group
- compound
- methotrexate
- gtp3
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical class C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims description 119
- 229960000485 methotrexate Drugs 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 38
- 239000007983 Tris buffer Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 28
- 201000004681 Psoriasis Diseases 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 125000001924 fatty-acyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 230000001363 autoimmune Effects 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 241000700159 Rattus Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 239000007787 solid Substances 0.000 description 18
- 231100000419 toxicity Toxicity 0.000 description 17
- 230000001988 toxicity Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 108010022394 Threonine synthase Proteins 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 102000004419 dihydrofolate reductase Human genes 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 102100028314 Filaggrin Human genes 0.000 description 11
- 101710088660 Filaggrin Proteins 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 230000005951 type IV hypersensitivity Effects 0.000 description 10
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 229960002537 betamethasone Drugs 0.000 description 9
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000376 reactant Substances 0.000 description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 208000005775 Parakeratosis Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000002682 anti-psoriatic effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 231100001231 less toxic Toxicity 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000989747 Maba Species 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- -1 methotrexate compound Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 4
- 239000005460 tetrahydrofolate Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 101100248451 Arabidopsis thaliana RICE2 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101100266802 Escherichia coli (strain K12) ychF gene Proteins 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 101100167281 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CIN4 gene Proteins 0.000 description 3
- 101100016060 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gtp1 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 229960004311 betamethasone valerate Drugs 0.000 description 3
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000004820 halides Chemical group 0.000 description 3
- 150000001261 hydroxy acids Chemical class 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- CYNARAWTVHQHDI-UHFFFAOYSA-N (2,4-diaminopteridin-6-yl)methanol Chemical compound N1=C(CO)C=NC2=NC(N)=NC(N)=C21 CYNARAWTVHQHDI-UHFFFAOYSA-N 0.000 description 2
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- LWCXZSDKANNOAR-UHFFFAOYSA-N 4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(O)=O)C=C1 LWCXZSDKANNOAR-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101150041602 GTF1 gene Proteins 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010019637 Hepatic atrophy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101500025652 Homo sapiens FasL intracellular domain Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010007666 IMP cyclohydrolase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100020796 Inosine 5'-monophosphate cyclohydrolase Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- WVMBPWMAQDVZCM-UHFFFAOYSA-N N-methylanthranilic acid Chemical compound CNC1=CC=CC=C1C(O)=O WVMBPWMAQDVZCM-UHFFFAOYSA-N 0.000 description 1
- 108010045040 Phosphoribosylaminoimidazolecarboxamide formyltransferase Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 238000011804 SKH1 hairless mouse Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- HQDIRMPLDXINKZ-BARLVKFPSA-N [2-carbamoyl-4-[[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]amino]-1H-imidazol-5-yl]phosphonic acid Chemical compound N1C(C(=O)N)=NC(NC2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1P(O)(O)=O HQDIRMPLDXINKZ-BARLVKFPSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- GFABNNMTRVBLPZ-QRPNPIFTSA-N azanium;5-[[(4s)-4-amino-4-carboxybutanoyl]amino]-2-nitrobenzoate Chemical compound N.OC(=O)[C@@H](N)CCC(=O)NC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 GFABNNMTRVBLPZ-QRPNPIFTSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011613 copenhagen rat Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940117927 ethylene oxide Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 101150031572 gtfA gene Proteins 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001884 polyglutamylation Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ty WO 00/34281 PCT/A U99/01073
Methotrexate derivatives
The present invention is concerned with derivatives of methotrexate (MTX), compositions containing the derivative and to methods of treatment involving use of these MTX derivatives.
MTX can bind to active sites on the enzyme dihydrofolate reductase (DHFR) and through competitive inhibition block the formation of tetrahydrofolates (THF) needed in the biosynthesis of DNA and RNA. MTX also inhibits other folate dependent enzymes.
The ability of MTX to inhibit nucleic acid synthesis has been used to treat . abnormal cell growth. Since actively proliferating cells are more sensitive to MTX, it can be used to selectively impair cancerous cell growth. MTX is a widely used anti-cancer agent used to treat neoplastic diseases. MTX also acts as an antiproliferative and immunoregulator and can be employed in the treatment of psoriasis and rheumatoid arthritis.
Oral MTX is currently used for the treatment of moderate or severe arthritis and recalcitrant psoriasis. The weekly dose is 2.5 to 25 mg. Use of this drug is restricted by its toxicity with the major long term side effect being liver damage. Attempts to reduce toxicity and improve efficacy in psoriasis treatment by applying MTX topically have met with little or no success, possibly due to either poor dermal penetration or residence time of the drug in the skin.
In a first aspect, the present invention provides
A
M—[Y]q—NH—C—CX,-O—R, :
B in which M is methotrexate or an analogue thereof,
A=H, CX;-0-R; or halogen;
B=H, CX>-O-Rs or halogen;
X is independently H or halogen; nis 0 or greater than or equal to 1;
Y is a linker group, and where n is greater than 1, each Y is the same or different;
Ry,Rz, and Rs are the same or different and are either hydrogen, substituted or unsubstituted methyl, ethyl, a saturated or unsaturated fatty acyl group, with the proviso that when n is 0 or 1, and A is CH,-O-R; and/or B is CH,-O-R, then Ry, R; and R; are not selected from a fatty acyl group; with the proviso that when n is greater than or equal to 2, and A is CH,-O-R, and/or B is CH,-O-Rs, and at least one of R,, R; and Rs is a fatty acyl group, then -[Y].- is other than -(AA),~ or -Y-(AA),.;-, where AA is an amino acid.
Examples of analogues of methotrexate are described in the prior art. See, for example, .A.L Jackman ed (1999). "Antifolate Drugs in Cancer Therapy" Humana Press,
Totowa, New Jersey, Matsuoka, H and Mihara, M (1998). " The synthesis and biological evaluation of new methotrexate derivatives in rheumatoid arthritis. Drugs of the Future 1998. 23(9);1015-1022; and Degraw, J et al. (1995) "New analogs of . methotrexate in cancer and arthritis". Current Medicinal Chemistry 2:630-653, the disclosures of which are incorporated herein by reference. }
Preferably M is methotrexate.
Examples of linker groups that are useful in the present invention include: a) a linker with an amino group to M and a carboxyl group to the
NHC(A)(B)CX,O0R, group, for example, an amino acid or antibiotic. b) a linker with an amino group to M and a sulphonic acid group to the
NHC(A)(B)CX,OR, group, for example, 2-aminoethanesulphonic acid (taurine). c) a linker with an hydroxyl group to M and a carboxyl group to the
NHC(A)(B)CXOR, group. The linker may be an hydroxy acid. The hydroxy acid may be analogue of an amino acid in which the amino group of the amino acid is replaced by an hydroxy group. Examples of hydroxy acids include glycolic acid (HOCH,COOH); lactic : acid (HOCH(CHHCOOH; 1 hydrowy-butyrie asid [IOCILCILCILCOOIL ¢-hiypdioxg= caproic acid; 10-hydroxy-decanoic acid; 2-hydroxy-caproic acid; 2-hydroxybutyric acid; 3-hydroxy-butyric acid, etc. The use of these acids allows linkage of the Tris, or Tris- conjugates to the drug via a labile ester bond rather that via the more stable amide bond. d) a linker with an hydroxyl group to M and a sulphonic acid group to the
NHC(A)(B)CX;OR, group, for example, 2-hydroxyethanesulphonic acid (isethonic acid). e) a linker with an hydroxyl group to M and a reactive halide group to the
NHC(A)(B)CX,OR, group, for example, 2-chloroethanol. f) a linker having an hydroxy group and an aldehyde group, for example, p- hydroxybenzaldehyde,
+
R . ie WO 00/34281 PCT/AU99/01073 3 g) a linker having a halide group and an carboxyl group, for example, 2- chloroacetic acid; h) a linker having two reactive halide groups, for example, 1,2-dibromoethane; and 1) an alkylene oxide, for example, ethyleneoxide.
The NHC(A)(B)CX,OR, group may be attached to the a or y carboxyl group of the methotrexate compound. Most preferably, the -NHC(A)(B)CX,OR, group is attached to the y carboxyl of the methotrexate compound, optionally by the linker.
Where Y is an amino acid it may be any suitable amino acid including, natural and non-natural amino acids and analogues thereof. Preferably the amino acid is glycine.
Preferably R,, R; and R; are each H.
Preferably n is in the range 0-5. . In a preferred embodiment of the invention, M is methotrexate and -[Y],- is -[AA].-, where AA is an amino acid. Preferably AA is glycine and nis 1. Where n >2, each AA need not be the same amino acid. ’ A preferred methotrexate derivative is methotrexate-y-glycine-TRIS (MTX-y-
GI).
In a second aspect, the present invention provides a pharmaceutical composition incorporating a compound of the formula I as defined above and a pharmaceutically acceptable carrier or diluent.
In a preferred form of the composition of the invention, M is methotrexate. Y is glycine and nis 1.
One preferred methotrexate derivative is methotrexate derivative is methotrexate-y-glycine-~Tris.
Compositions suitable for oral administration include liquid solutions, capsules, suspensions, emulsion etc.
The composition of the invention may be in tablet form incorporating the usual tablet formulation ingredients.
Composition suitable for parenteral administration include aqueous and non- a0 aqueous injectable solutions or emulsions.
Formulation suitable for topical administration may be in the form of a cream, gel, paste, salve, poultice, nasal spray, pulmonary aerosol or foam incorporating the compound of the present invention.
The composition of the invention may be in the form of suppositories, pessaries, tampons, creams, gels, pastes, lotions, implants, patches or foams.
The composition of the invention may be in the form of an implant.
The composition of the invention may be in the form of a liquid aerosol or powder for administration to the lung.
The dosage level of the MTX derivative of the present invention in the pharmaceutical composition may be sufficient to effect a prophylactic or therapeutic response in the selected time frame.
The present invention also provides a method of treatment of cancer or a disease with an autoimmune component in a subject, the method including administration of a prophylactically or therapeutically effective amount of a compound of the formula I given above.
Accordingly, in a third aspect, the present invention provides a method of treatment of a disease with an autoimmune component or a cancer in a subject, the method including administration to the subject of an effective amount of a compound in accordance with of formula II: :
Pp i
M= Yl NH=C—CX%~0— Re
E wherein:
D=H or CX,~O-R, or halogen;
E=H or CX;-0-Rs or halogen;
X 1s as defined above; n is as defined above;
Y as defined above; and
R4, Rs and Rg are the same or different and either hydrogen, substituted or unsubstituted methyl, ethyl or fatty acyl groups with either saturated or unsaturated bonds.
The disease with an autoimmune component may be any condition where immunosuppression is called for. For example, the disease with an autoimmune component may be psoriasis or rheumatoid arthritis.
The disease with an autoimmune component may be inflammatory bowel disease or Crohn's disease in a subject.
Preferably the compound used in the method of the third aspect is a compound of formula I.
The method of treatment of the present invention may be achieved by any suitable route, for example, oral, parenteral, implant. and topical.
Yi WO 00/34281 PCT/AU99/01073
The dosage level of the MTX derivative of the invention depends on the nature and severity of the condition being treated but generally the administered amount is sufficient to produce a prophylactic or therapeutic effect. Pharmaceutical compositions in accordance with the invention may contain the MTX derivative in an amount in the 5 range of about 0.001 to about 90% of the composition. A composition in an oral form, for example, a tablet, may contain up to 85% of the MTX derivative, preferably about 2 to 60% of the oral composition. The concentrations here set forth are provided by way of description only and not by way of limitation.
In order that the invention may be more readily understood, the following non- limiting embodiments are provided.
BRIEF DESCRIPTION OF DRAWINGS: : Figure 1 is a boxplot demonstrating the effect of oral MTX-y-GT, MTX-y-GTP1 and
MTX-y-GTP3 in the rat assay of delayed type hypersensitivity footpad oedema. MTX-y-GT and MTX-y-GTP1 are both active in this assay as is
MTX. MTX-y-GTP1 is statistically more effective than MTX (p=0.021).
Figure 2 shows the effects of MTX and MTX-y-GT in the rat adjuvant-induced arthritis model. The results indicate that MTX-y-GT is, at the two lower doses, equipotent to MTX in delaying the onset of joint inflammation in this model.
Figure 3 shows the suppressing effect of MTX-y-GTP3 on epidermal DNA synthesis following UVB irradiation. After UVB irradiation mice respond with an initial suppression of DNA synthesis followed 48h later by a marked increase in DNA synthesis. MTX-y-GTP3 is at least as active as MTX in suppressing this pulse of synthesis.
Figure 4 shows the suppressing effect of MTX and MTX-Tris conjugates on mitotic activity in epidermal cells following UVB irradiation.
Figure 5 shows Filaggrin expression from the SPA proof-of-principle trial. The figure shows total filaggrin expression following topical MTX-y-GTP3 or MTX treatment versus the response with betamethasone. Patients in the upper right hand quadrant responded positively to both betamethasone and 0.5% MTX-y-
GTP3 (indicated by *; patients 1, 2, 4, 6 & B). Patients 5, 9 and 10 responded to betamethasone but failed to respond to 0.5% MTX-y-GTP3. MTX (circles) and 1.0% MTX-y-GTP3 (squares) also showed positive patients in a similar manner. The correlation between response to betamethasone and MTX-y-
GTP3 suggests that there are two main groups in the trial: responders and non- responders.
Figure 6 is a box plot showing the pooled results for filaggrin expression in the stratum granulosum of SPA patients treated with oral MTX-y-GTP3 or MTX compared to betamethasone treatment. There is a statistically significant effect of the positive control betamethasone versus its vehicle. The comparison of 0.5% MTX-y-GTP3 with its vehicle gives a borderline significance of 0.08.
Figure 7 shows granularity.parakeratosis ratios for patients treated with 1.0%, 0.5%
MTX~y-GTP3 solution, 0.5% MTX and 0.05% betamethasone valerate cream. 1.0% MTX-y-GTP3 is showing positive results with this early indicator of plaque resolution.
Abbreviations:
AICAR phosphoribosylaminoimidazolecarboxamide
APA 4-amino-4-deoxy-N10-methylpteroic acid }
DAHMP 2,4-Diamino-6-hydroxymethylpteridine
DCC 1,3-dicyclohexylcarbodiimide
DCM dichloromethane
DECP diethyl cyanophosphonate
DMA N,N-dimethylacetamide
DMAP 4-dimethylaminopyridine
DMF N,N-dimethyl formamide
Et, 0 diethylether
EtN'Pr di-isopropyl ethyl amine
EtOAc ethyl acetate oT aT giguine=Tiis I
GTPI glycine-Tris monopalmitate
GTP2 glycine-Tris dipalmitate
GTP3 glycine-Tris tripalmitate
HOAc acetic acid
HOSu N-hydroxysuccinimide
MABA N-methyl aminobenzoic acid
MTX methotrexate
MTX-y-GT methotrexate-y-glycine-Tris
MTX-y-GTP1 methotrexate-y-glycine-Tris monopalmitate
MTX-y-GTP2 methotrexate-y-glycine-Tris dipalmitate te WO 00/34281 PCT/AU99/01073 . MTX-y-GTP3 methotrexate-y-glycine-Tris tripalmitate
OMe methyl ester
P05 phosphorus pentoxide
PmCl palmitoyl chloride
PPh3 triphenyl phosphine
RM reaction mixture
RT room temperature tBu tert Butyl ester tBuOAc tert Butyl acetate
TFA trifluoroacetic acid
TPPO triphenylphosphine oxide
Z-GT benzyloxycarbonyl glycine-Tris . Z-GTP1 benzyloxycarbonyl glycine-Tris monopalmitate
Z-GTP2 benzyloxycarbonyl glycine-Tris dipalmitate
Z2-GTP3 benzyloxycarbonyl glycine-Tris tripalmitate
Preparation of methotrexate-y-glycine-Tris (MTX-y-GT)
Glycine-Tris (GT) 0]
HN A (5h
H
OH
CH 1aN204
Mol. Wt. 178.19
N-(benzyloxycarbonyl)-glycine-Tris (Z-GT; USP 5,952,499) (1.70 g, 5.44 mmol) was dissolved in ethanol (60 ml) with warming and stirring. After cooling to room temperature by immersion in a cool water bath, palladium-on-carbon (10%, 0.14 g) was added and the system evacuated and filled with hydrogen gas three times. The mixture was stirred vigorously under a hydrogen atmosphere at room temperature for 19 h then filtered through two glass-fibre (GF/A) filter papers (rinsing with fresh ethanol (approx. 10 ml)). The filtrate was evaporated leaving GT (0.97 g, 100%) as a white solid 'H n.m.r. (d-DMSO) 4 2.1, br s, NH; 3,1,5,NCH,CO; 3.55, s, 3xCH,0; 5.0, br s, 3xOH; 7.95, br s, NH.
MTX-a-tBu-y-GT ne 0 \Pt 0]
PUN
2 H l H OH
AS Ne
NH; N N
MTX-o-tBu-v-GT )
C30H 42N1003
Mol. Wt: 670.72 .
Methotrexate-o-tert-butyl ester (MTX-a-tBu; USP 5,952,499) (0.438 g, 0.86 mmol) was dissolved with stirring, in DMF (4ml). HOSu (0.12 g. 1.03 mmol) was added and stirred until dissolution occurred. DCC (0.27 g. 1.29 mmol) was added and the resulting mixture stirred at room temperature under nitrogen for 16 h. More DCC (100 mg) was added and the mixture stirred for a further hour. GT (0.23 g., 1.29 mmol) in
DMF (1.5 ml) was added and the resulting mixture stirred for 54 h. The mixture was filtered through glass wool and the filtrate evaporated. The residue was radially chromatographed on silica gel. Elution with 15% methanol in DCM afforded the title compound (0.33 g. 57%) as a yellow solid. '"H n.m.r. (d-DMSO) 5 1.39, 5, C(CHa);; ) 1.96, iti, glu-B-CHo; 2.24, i, giu=y-CHs, 3.21, 5, Nite, 3.32, 4, j 6 Hz, 3xCH;0H, 3.70, TT d, J 6 Hz, gly NCH,CO; 4.22, m, glu-o-H; 4.69, t, J 6 Hz, 3xOH; 4.79, s, ArCH,n 6.62, brs, NHy; 6.82, 7.72 AA'BB', ] 9Hz, ArH; 7.14, s, tris NH; 7.46, br s, NH; 8.10, t, J 6Hz, gly NH; 8.27, d, J THz, glu NH; 8.56, s, H-7, Mass spectrum [electrospray ionization, positive ion mode (ES(+))] m/z 671 (M+1)
rt WO 00/34281 PCT/AU99/01073
MTX-3GT
CO H 0 0 : 2 H ; N N OH
NH, TY H OH
N
PN = | MTX-y-GT nH NON
C 26H 3aN 1903
Mol. Wt: 614.62 ] 5 MTX-a-t-Bu-y-GT (0.459 g, 0.68 mmol) was dissolved, with stirring, in TFA (3 ml). The solution was stirred at room temperature for 1.5 h and the solvent evaporated under vacuum. The residue was dissolved in water and the solution pH (approx. 2) was : adjusted to 6 with aqueous sodium bicarbonate solution (1g in 75 mi). Aqueous HOAc (10%) was added to pH 4. The solution was freeze-dried and the residue purified by flash chromatography then radial chromatography (twice) on silica gel. Elution with 1- 3% water in 3:5 methanol:chloroform afforded the title compound (0.086 g, 21%) as a yellow solid. '"H n.m.r. (ds-DMSO) 5 1.96, m, glu-B-CH,; 2.14, m, glu-y-CH,; 3.19, S,
Nme; 3.5-3.7, m, 3xCH,OH + 3xCH,OH; 3.95, m, gly NCH,CO; 4.41, m, glu-o-H; 4.76, s, ArCH;N; 5.37, br s, NHy; 6.61, br s, NH,; 6.84, 7.62 AA'BB', J] 9Hz, ArH; 7.60, m, glu NH; 7.71, s, tris NH; 8.23, t, J 6Hz, gly NH; 8.57, s, H-7, ES(+) mass spectrum m/z 615 (M+1), 637 (M+Na), 659 (M+2Na).
Preparation of methotrexate-y-glycine-Tris mono, di and _tripalmitate (MTX~y-
GTP1, MTX-v-GTP2, MTX-y-GTP3
The title compounds can be prepared as described in USP 5,952,499 or via the following procedures.
Synthesis of 2,4-Diamino-6-hydroxymethylpteridine (DAHMP)
NH, NH,
CL me py
HNN N~ HCI HN" NN
MW 228.65 MW 192.19
Ref: Rosowsky ef al, J. Med. Chem., 1985, Vol. 28, No. 5, 660-667.
Reactants:
DAHMP hydrochloride (69.04g, 0.30mol) x
HOAC (120ml)
H20 (1200ml)
Procedure:
DAHMP HCI was dissolved (with heating to 80°C) in aqueous acetic acid. The solution was filtered through glass wool and cooled to 45°C. The pH was adjusted to 5.3-5.6 (monitored with pH paper) with concentrated ammonium hydroxide solution.
RM cooled to RT and filtered. The yellow/caramel coloured solid collected was washed twice with water then dried in a vacuum oven over P205 at 80°C overnight x 2 to afford the desired DAHMP (free base) (52.90g, 92%) as a golden/tan coloured solid. 4-[[(2,4-Diamino-6-pteridinyl) methyl)methylamino]-benzoic acid, or 4-amino-4- : deoxy-NI O_meothplpternic acid (APA) RR Cl
CO.H
NH, NH, gr 2
VY bl oH (1) PPhy/Br, NTS Ny NT
HN NN (2) MABA/ HN NN
EtN'Pr,
MW 192.19 dihydate MW 361.37
Ref: Kralovecet al, J. Med. Chem., 1989, Vol. 32, No. 11, 2426-2431.
Rosowsky et al, J. Med. Chem., 1985, Vol. 28, No. 5, 660-667.
fe WO 00/34281 PCT/AU99/01(73
Reactants:
DAHMP (15.00g, 78mmol)
Bra (3eqv, 12.1ml, 37.53g, 0.23mol)
PPh3 (3eqv, 61.44g, 0.23mol)
DMA (187ml)
MABA (13.57g, 89mmol)
EtNiPr2 (3eqv, 40.6ml, 30.1g, 0.23mol)
Procedure:
Bra was added slowly via syringe to an ice-cooled, stirred mixture of PPh3 in
DMA under nitrogen. Solid DAHMP was added (nitrogen "breeze" over RM) and RM stirred at RT for 24h. The amine was added via syringe, followed by solid MABA ’ (nitrogen "breeze"). RM was allowed to stir at RT for 67.5h. RM poured into aqueous sodium hydroxide solution (0.33M, 125ml), the resulting precipitate filtered off and the . 15 filtrate adjusted to pH 5.5 with aqueous acetic acid (10% v/v). The precipitate was collected, washed sequentially with water, cold ethanol, and ether, and dried in a vacuum oven at 40°C for 4 days to afford a yellow solid (25.79g). To remove the TPPO and MABA contaminants, the crude product was stirred in 3:2 methanol:ethanol (50mi) at RT for 50h, filtered, washed with Et,0 (x2), air-dried and evacuated to give APA (24.48g, 87%) as a yellow solid.
L-Glutamic Acid-o-tBu-yMe ester
CO H (1) tBUOAC, HCIO 4 COtBu ~~ : Le SN
HoN CO Me (2) NaHCO 3 HoN CoO Me
MW 161.16 MW 217.26
Ref: Rosowsky ef al, J. Med. Chem., 1981, Vol. 24, No. 12, 1450-1455.
Reactants:
L-Glutamic acid 5-Me ester (17.54g, 0.108mol) tBuOAc (200ml) 70% HClO4 (10.9ml, 0.12mmol)
Procedure:
HClO4 was added slowly to a suspension/partial solution of the substrate in tBuOAc (during acid addition, substrate started to dissolve). RM was stirred in loosely stoppered flask at RT for 40h. RM extracted with 0.SN HCI (2 x 200ml, 1 x 150ml).
The aqueous layer was cooled in ice/salt/dry ice bath (> -5°C) and neutralized with solid sodium hydrogen carbonate (until pH approx. 8 and no more NaHCO3 dissolves) with the temperature of the solution being maintained at approx. -4°C. The mixture was extracted with ether (RT, 4 x 200ml), the combined organic layers washed with brine (100ml), dried (MgSO4) and evaporated (rotary evaporator, then oil pump, without heating) to afford the desired product (10.77g, 45%) as an almost colourless, viscous oil which partially solidified on storage at —20°C.
MTX- a-tBu-y»Me diester :
COH
NS NSN
HNN
2 Dihydrate MW 361.37
APA
(1) (EtO) 2POCN | 2) COotBu 4 ipr,NE y HoN I~ co Me 0] co tBu
NH, A N">""co Me B
VY he NX H
A AA MW 524.59
HN "N° 'N
Ref: (1) Rosowsky ez al, J. Med. Chem., 1981, Vol. 24, No. 12, 1450-1455. (2) Kralovec et al, J. Med. Chem., 1989, Vol. 32, No. 11, 2426-2431.
Reactants:
APA (8.56g, 23.7mmol)
EtN'Pr2 (9.0ml, 51.7mmol)
DMF (460ml)
wr WO 00/34281 PCT/AU99/01073
DECP (7.20g, 44.1mmol)
L-Glutamic Acid a-tBu-y-Me ester (7.26g, 33.4mmol)
EtNiPr2 (8.5ml, 48.8mmol)
Procedure:
APA (granulated) was added portionwise over 10 minutes to a solution of DECP and EtN'Pr2 (first portion) in DMF (400ml). The solution was immersed in an oil bath (pre-heated to 80°C) for 2 minutes (internal temp. to 34°C). The flask was removed from the bath and stirred for 30 mins (internal temp. 22°C). The second portion of
EtN'Pra was added followed by glutamate in DMF (50+10ml rinse). RM was stirred at room temperature under nitrogen for 14 h (overnight). A solution of NaHCO3 (1.80g, 21mmol) in water (60ml) was added, the mixture stirred for 30 mins and then ‘ evaporated (rotary/oil pump, 45°C). The residue was dissolved in chloroform (approx. 400ml) and the solution washed with water (300ml) and 5% aqueous sodium } 15 bicarbonate solution (200ml). The organic layer was washed with brine (30ml), dried (MgSO04) and evaporated. The residue (brown, viscous gum) was filtered through a small silica column with 5% methanol in DCM to remove polar impurities and the resulting product flash chromatographed on silica gel, eluting with 7-12% methanol in
DCM to afford the product in three fractions: 1 (trace impurity) (2.17g, 18%); 2 (high purity) (4.40g, 36%); and 3 (trace impurity) (2.77g, 22%) as bright yellow solids.
MTX-o-tBu ester (This is the same intermediate as described in USP 5,952,499 — Compound IV)
O COtBu
NH, jeg NT CO Me
PON MW 524.59
HN” NN
Ba(OH),.8H,0 v O CO tBu
NH, NCO H
N H
NTS T° N
AAA! MW 510.56
HN” "NN
Ref: Rosowsky er al, J. Med. Chem., 1981, Vol. 24, No. 12, 1450-1455.
Reactants:
MTX-o-tBu-y-Me diester (5.00g, 9.5mmol)
Ba(OH)7.8H20 (1.82g, 5.8mmol)
Ethanol (95ml)
Water (110ml)
Na2504.10H20 (1.93g, 6.0mmol) in water (10m)
Procedure:
The first three reactants were mixed and stirred at RT in a loosely-stoppered flask for 19 h. Sodium sulfate in water was added and the mixture stirred for a few : minutes (BaSO4 precipitate seems to form immediately) then filtered through 2xGF/A filter papers on a No. 3 or 4 glass sinter. The filtrate was adjusted to pH 5 with 10%
HOAC in water. The resultant suspension (gelatinous precipitate) was refrigerated for 30m and then the solid collected by filtration using a No. 1 filter paper on a glass sinter.
The collected solid was air-dried overnight (still on the filter paper in the funnel) then evacuated (oil pump) to afford the desired product (4.41g, 91%) as a bright orange/yellow solid.
or WO 00/34281 PCT/AU99/01073
Z-GTP3 (+ Z-GTP2 + Z-GTPI1) 1 H OH
N
(re NY Xo oH .
ZGT OH
PmCl(2eqv)
Et;N
DMF/CH ,Cl, (1:4) 1 HN —op Je N. —op
H go OPm + H 0 OPm } OPm OH
ZGTP3 0 ZGTP2
J H OPm
ONG
O OH
ZGTP1
Reactants:
Z-GT (50.00g, 0.16mol)
PmCI (108ml, 97.85g, 0.356mol)
Et3N (100ml, 72.4g, 0.72mol)
DMF (450ml)
DCM (1.60 + 0.20L)
Procedure:
Z-GT was dissolved in DMF in a 5L, three necked round-botiomed flask. DCM (1.6L) was added and the stirred solution cooled with an ice-salt bath for 1h. A solution of PmCI in DCM (100 ml) was added dropwise over 2h and the bath temperature maintained at -13 to -10°C The dropping funnel was rinsed with DCM (100 ml). The
RM was stirred at the same temperature for a further 2h and then at 4°C over the weekend. The solvent was removed under vacuum (the precipitate that appeared during the evaporation was filtered after the removal of DCM in order to remove DMF efficiently). The residue was extracted with EtOAc (400 ml) then DCM (800 ml) (EtOAc extract resulted in precipitation on washing the extract with brine or water).
The combined organic extracts were washed with brine and dried (MgSO4). Solvent removal under vacuum gave the crude product as a yellow wax (133.48g). HPLC analysis indicated a mixture of Z-GTP3, Z-GTP2 and Z-GTP1 in a ratio of 28.8%, 47.4% and 23.8% respectively.
MTX-a-tBu-y-GTP3
Oo CO ABu
Le or NT coH
NS bl x
LA J MW 510.56
HoN A NN
GTP; | DCC/DMAP
O CO. tBu = GTP,
NH, NY
N H
YY
ENF MW 1385.91
HN” "N° °N :
Reactants:
MTX-o-tBu ester (11.00g, 21.5mmol)
DCC (1.2eqv, 5.50g, 26.7mmol)
GTP3 (1.1eqv, 21.32g, 23.9mmol)
DMAP (0.1eqv, 258mg, 2.1mmol)
DMF (86ml) . 15 DCM (240m) ee
Procedure:
MTX-a-tBu ester was dissolved, with stirring, in DMF. DCM (200ml) was added. DCC was added and the solution stirred for 20 mins. GTP3 in DCM (70ml) was added dropwise over 10 mins. DMAP was added and the RM stirred at RT under nitrogen overnight (24 h). The RM was filtered to remove white solid, urea by-product from DCC and concentrated (rotary/oil pump, 50°C) to remove DMF. The residue was dissolved in DCM, refiltered and evaporated. The residue was dissolved in EtOAc¢/DCM (150/20ml), washed with brine, dried (MgSO4) and evaporated. The residue was divided into halves and each was flash chromatographed on silica gel, eluting the first be WO 00/34281 PCT/AU99/01073 . half with 5% methanol in DCM and the second half with 3.7-4.4% methanol in DCM.
Re-chromatography of the impure fractions afforded the product in two fractions (bright yellow solids), (1) (>95%purity) (17.18g, 58%) and (2) (90-95% purity) (4.83g, 16%).
Further elution with 8-10% methanol afforded a third fraction containing a bright yellow solid by-product.
MTX-y-GTP3
O CO.tBu = GTP,
NH, NTT
N H
SOR °
Z MW 1385.91
HN N
TFA v O CO. H = GTP
NH, or NY 3
CX ;
PN | F MW 1329.81
HoN A NN
Reactants:
MTX-a-tBu-y-GTP3 (0.86g, 0.62mmol)
TFA (1.7ml, 22mmol)
DCM (5ml)
Procedure:
TFA was added dropwise to an ice-cooled, stirred solution of the substrate in
DCM. The RM was allowed to warm to RT then stirred under nitrogen for 5.5 h. The
RM was placed at 4°C overnight then diluted with DCM (25ml) and washed with aqueous, sodium bicarbonate solution (5% w/v, 35ml) (check that pH>7). HOAc (glacial, 1.8ml) was added and mixture shaken (check that pH~4). The organic layer was washed with water (2x25ml) (the emulsion was broken by addition of a little NaCl & methanol & fresh solvents, swirling and warming), dried (MgSO4) and evaporated. The residue was flash chromatographed on silica gel, eluting with an 8-30% step gradient with methanol in DCM (3X4%; 2X5% steps) to afford the product in three fractions:- (1) (trace higher Rf by-product, 187mg), (2) (higher purity, 476mg) and (3) (trace lower
Rf by-product, 79mg). All fractions were yellow solids and of quite high purity. Fraction (2) -> 97.25% purity (by HPLC). Yield = 742mg, 90%.
MTX-y-GTP1 and MTX-y-GTP2 can be prepared in a similar manner from Z-
GTP1 & 2 respectively.
In vitro DHFR Inhibition
Dihydrofolate reductase (DHFR) is a target enzyme of MTX. It catalyses the following reaction:
DHFR
Dihydrofolate + NADPH +H" — Tetrahydrofolate + NADP"
Its activity can be measured in vitro by following the rate of NADPH oxidation at 340nm.
Method:
The inhibition of DHFR by MTX, MTX~y-GT and MTX~y-GTP, was measured as described by Imbert AM, Pignon T, Lena N (1983) "Enzymatic assay for methotrexate with a centrifugal analyser (Cobas-Bio)" Clin Chem, 29(6):1317-1318.
Results:
MTX-y-GT inhibited DHFR in the same concentration range as MTX (Table 1).
Table 1. Inhibitory activity of MTX and MTX-y-GT on DHFR at 2.86 nM
MTX 45.5
MTX-y-GT 36.4
The inhibitory activity of MTX-y-GTP1 was also tested. The concentration required to cause a 50% inhibition of DHFR was 76nM. This is 16X less active than
MTX which causes 50% inhibition of DHFR at 4.8nM.
MTX-a-GTP; did not inhibit DHFR under these conditions.
MTX-y-GTP; and MTX-y-GTP; were not tested as their solubility characteristics are incompatible with the assay system.
Ln WO 00/34281 PCT/AU99/01073
Investigation of MTX-y-GT, MTX-y-GTP1 and MTX-y-GTP3 using the delayed type hypersensitivity (DTH) response in the rat
Delayed type hypersensitivity (DTH) is an immune response which can be used to assess the action of various therapeutic agents. It can be demonstrated by sensitising an individual to a compound, and then on challenge with the same compound, observing the development of oedema at the site of challenge. MTX has an immunosuppressive effect which reduces oedema, and this reduction in DTH response has been used to assess one aspect of the efficacy of MTX-y-GT, MTX-y-GTP1 and MTX-y-GTP3.
Methods: y
Copenhagen (COP) rats had their abdomens shaved and 100 ul of 0.5% . dinitroflurobenzene (DNFB) in acetone was applied daily for 3 days. Concurrently, the rats were administered orally either, soy oil, MTX (0.5 mg) or equimolar amounts of
MTX-y-GT, MTX-y-GTP1 or MTX-y-GTP3 daily for 5 days. On day 7, rats were anaesthetised with methoxyflurane and the footpad volume measured immediately prior to the addition of 25 pl of 0.2% DNFB in acetone to the left footpad. Under anaesthesia, footpad volume was measured at 23h. Plethysmography (the measurement of the volume of an object by observed changes in volume after immersion), using a laboratory fabricated oncometer, was used to determine the volume of the footpad. The nett oedema was calculated by subtracting the volume of the foot at time 0 from time 23h.
Drugs:
MTX (1mg/ml) in Soya oil
MTX-y-GT - (1.4 mgs/ml) in soya oil — (Batch QY5-64MXS)
MTX-y-GTP1 - (1.88 mg/ml) in soya oil — (Batch GB4-99 NB00077-p50)
MTX-y-GTP3 - (3 mg/ml) in soya oil ~ (Batch QY 4-41 FP)
Control - soya oil
Results:
The nett footpad oedema data is presented in Figure 1.
The mean nett footpad oedema was significantly less in those rats treated with
MTX, MTX-~y-GTP1 and MTX-v-GT, but not MTX-y-GTP3 when compared with control rats (Table 2). As well, the nett footpad oedema from the MTX-y-GTP1-treated rats was significantly less (p = 0.021) than that in the MTX-treated rats
Table 2: Mean, SD and p values of data
Treatment n Mean SD p value when oedema compared to
SU (.:)) NS ©.) 1: {+1
Control 38 0.363 0.254 -
MTX 8 0.216 0.150 0.044"
MTX-y-GTP3 22 0.327 0.325 0.59
MTX-y-GT 18 0.192 0.237 0.0195"
MTX-y-GTP1 11 0.055 0.050 <0.0001" * statistically significant
Discussion: )
DTH is an in vivo T cell-dependent immune response manifested as an inflammatory reaction after antigenic challenge. Thus these results indicate the . immunosuppressive effects of MTX-y-GT and MTX-y-GTP1 are at least equal to or perhaps more effective than MTX.
The ability of MTX and its Tris-conjugates to inhibit proliferation of cultured cells were assessed.
Methods:
The effect of MTX and MTX-Tris-conjugates on cell proliferation was studied using routine cell culture procedures. The following cell lines were tested: ) JURKAT (human deute T-ceil fetkderniidy — TT TTT
Swiss mouse fibroblast (3T3) cells
CCRF-CEM (CEM) human T-cell leukaemia
JURKAT cells were cultured in the presence of drug for 64 h whilst 3T3 and
CEM cells were cultured for 48h and 96h respectively in the presence of compound. All studies were performed in 96-well plates and control wells contained no drug. Cell proliferation was then measured using the MTS or MTT detection: (D Marks, L Belov,
MW Davey, RA Davey, A Kidman. Leukemia Research 16, 1165-1173. “The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells.”
Sh, WO 00/34281 PCT/AU99/01073 - Results:
All conjugates inhibited proliferation but were less toxic to all cell types tested than the parent compound, MTX. Results are summarised in the Table 3.
Table 3. Effect of MTX and MTX-Tris conjugates on the proliferation of various cell types. ICso = concentration of compound at which cell growth is inhibited by 50% of control growth. sts | Jurkat | cem
MIXaGT | - | - | 3500889 [MIXy-GT | noeffer | ~~. | 05760)
MTXyGTPE | of. | oearan
MTX-aGTP2 | - | 10%00q2s6) | - - not tested; * no effect observed up to 250 nM; (n) Conjugate:MTX ratio.
Reduced activity is likely to be due to the modification of MTX on the a- or y-
COOH. /n vivo MTX is polyglutamylated (addition of (glu),) on the y-COOH and this is an important aspect of MTX toxicity. It increases intracellular retention and consequently results in a sustained block in tetrahydrofolate synthesis via DHFR. MTX-~ y-(glu), also have greater inhibitory effects on other enzymes involved in DNA and RNA synthesis including thymidylate synthetase and AICAR transformylase. Polyglutamate formation and accumulation may have unwanted effects in vivo as they form in significant amounts in some organs (kidney and liver) where they may give rise to unwanted toxicity due to prolonged intracellular retention.
Some of our conjugates (ie MTX-y-GT, MTX-y-GTP1 and MTX-y-GTP3) are modified on the y-COOH and are unlikely to be polyglutamylated thus explaining their reduced toxicity.
The y-COOH is also involved in cellular uptake and modification may reduce uptake. In our study, the various MTX~y-conjugates display differences in their effect on cell growth. MTX-y-GT is less inhibitory than MTX-y-GTP1 or 2. It could be postulated that whilst addition of GT impedes the drug uptake (and therefore toxicity) via the folate transport system, this effect may, in part, be over ridden by the addition of palmitate groups. It is likely that palmitate-conjugates enter the cell by endocytosis.
Whilst MTX-y-GT is less toxic to cells than the palmitoylated conjugates, it is more inhibitory to DHFR in a biochemical assay (see above). This suggests that it is the transport mechanism rather than direct enzyme inhibition that differentiates between
MTX-y-GT and MTX-y-GTP1 or 2.
It is widely reported that modification to the «-COOH reduces cell uptake to a greater extent than modification to the -y-COOH. Our results are consistent with this.
Both MTX-a-GT and MTX~GTP2 are much less toxic than MTX-y-GT and MTX-y-
GTP2, respectively.
Overall our results are consistent with literature reports. Some relevant references are listed:
Rosowsky ef al.; J. Med. Chem. (1984) 27, 600-604
Rosowsky ef al. J. Med. Chem. (1984) 27, 605-609
Rosowsky ef al., J. Med. Chem. (1981) 24, 1450-1455
Fan eral. (1991) Biochem. 30, 4573-4580. :
Testing of MTX and MTX-y-GT in the rat adjuvant-induced arthritis model. ]
Doses of 40, 15 and Sumol/kg of MTX have been shown by Baggott and co- workers (Arthritis Rheum 1998, 41:1407-10) to give dose-dependent inhibition of adjuvant induced arthritis in Lewis rats.
A similar model using Dark Agouti (DA) rats has been used to test the effect of
MTX-y-GT.
Method:
DA rats were injected subcutaneously with Freund's Complete Adjuvant into the tail base. Arthritis developed 10-12 days later in untreated rats. Rats were treated with
PBS (control) or molar equivalent doses of MTX or MTX-y-GT in PBS orally (by
FavapE) otiee ai day 0, six vais por treatment group. The effect of treatment on arthritis = = was monitored daily by assessing body weight and evidence of arthritis, which was quantified using an established scoring system. This involves giving a score from 0 to 4 for each paw (0= no evidence of arthritis or inflammation, 4= global swelling of the paw). The theoretical maximum score was 16 but rats were euthanased if a score greater than 12 was observed. In treated rats, in which mild arthritis occurred, the disease was followed beyond the treatment period to determine whether arthritis was delayed rather than suppressed or prevented.
Am WO 00/34281 : PCT/AU99/01073
Results:
The results of a single dose of MTX and MTX-y-GT at day 6 are shown in
Figures 1: Ato F
Conclusions:
MTX and MTX-y-GT were effective in delaying the onset of inflammation by 2. 4 days. At the doses tested and within experimental error the effects of the two compounds were indistinguishable. From the DTH rat footpad results it would be expected that MTX-y-GTP1 might also delay the onset of inflammation in this model.
MTX-y-GTP3 was negative in the DTH assay but shows activity in the human SPA trial in the treatment of psoriasis (see below). Its effect on adjuvant-induced arthritis in rats remains to be determined.
Toxicity of MTX-Tris Conjugates : 15 Whilst no experiment has been performed that specifically examines toxicity, observations have been made during experiments examining biological activity which indicate that MTX-TRIS conjugates have reduced systemic toxicity compared to MTX.
The following observations have been noted: 1. Experiments examining the effect of daily topical applications over three consecutive days of vehicle, MTX, MTX-y-GTP2 or MTX-y-GTP3 on UVB-induced erythema in female Skh-1 mice have been performed. During this study mice were assessed for toxic signs (dehydration, diarrhoea and anorexia) for 6 days followed by assessment at necropsy for gross signs of GIT toxicity (enlarged fluid-filled intestines), MTX-y-GTP2 and MTX-y-GTP3 appeared much less toxic than MTX and results are shown in the following table.
Toxicity results from topical application to Skh-1 hairless mice e—————————en eer ASAT t erento
TREATMENT SIGNS OF DEATH
: GRoss GIT
TOXICITY vehicle 0/24 0/24
MTX 4 mg/kg’ 5/24 8/24
MTX-y-GTP2 9.6 mg/kg’ 0/24 0/24
MTX-y-GTP3 11.7 mg/kg’ 0/14 0/14 'Equimolar amounts of MTX, MTX-y-GTP2 and MTX-y-GTP3 were used. They were formulated in oil/water cream:ethyl oleate (4:1) and 0.1ml was applied to each mouse. GIT = gastrointestinal tract.
In many mice treated with MTX, clinical signs of toxicity and at necropsy, enlarged fluid-filled intestines were prevalent. Histological examination of these intestines showed marked microvilli damage and necrotic mucosal cells. In comparison, neither GIT damage nor mortality were observed in the mice receiving MTX~y-GTP2 or
MTX-y-GTP3. In all mice, the liver and kidneys appeared normal. 2. In Delayed Type Hypersensitivity assays studies, Copenhagen rats were administered orally either soy oil, MTX (0.5 mg) or equimolar amounts of MTX-y-GT,
MiTX=p=GTF1 or MTX-7-GTT3 daily for 5 days, whilst being concurrently sensitised by ———— topical application of DNFB. Following challenge with DNFB and necropsy 24h later, the intestines from a representative group of rats were examined for gross changes and samples collected for histology.
All MTX-treated rats (#=7) had an enlarged stomach and intestines filled with milky fluid. Histology of these GIT samples revealed villi with thickened, inflammed cores, separation and sloughing of the epithelium and mucosal necrosis. This is indicative of mild to severe damage. Rats receiving MTX-y-GT (#=9) had a normal GIT with the exception of one animal which had an enlarged fluid-filled large intestine.
Macroscopic examination of the GIT from MTX-y-GTP1 (n=14) and MTX-y-GTP3
- (n=14) treatment groups revealed no gross abnormalities. Reduced histopathology was displayed in the GIT from rats receiving MTX-Tris conjugates. 3. In studies examining the effects of MTX and MTX-y-GT on adjuvant-induced arthritis in rats, the following observations were noted: a) Following a single oral dose of MTX or MTX-y-GT (40 umole/kg), diarrhoea was observed 1-2 days later in the MTX group. This was not evident in the MTX-y-GT and vehicle only groups. b) In a second experiment, rats were given 3 oral doses, 3 days apart. Toxic side effects (ruffled fur and ataxia) were evident in rats treated with MTX (5 umole/kg).
Consequently, these animals were euthanased earlier than originally planned. Post mortem showed marked changes in the GIT, particularly the small intestine which . appeared bloated and contracted. Histology showed marked crypt hyperplasia and loss of villous structure in the mucosa of the jejunum and the ileum. In some areas there was loss of both crypt and villous epithelium. The mesenteric lymph nodes of these rats were also enlarged. None of these effects was seen in the vehicle- and
MTX-y-GT-treated groups. In addition, peripheral blood samples from these MTX treated rats showed profound leucopaenia (approx. 2 x 10%/L), due largely to neutropaenia. Leucocyte counts in the vehicle control and MTX-y-GT groups were not different (approx. 30 x 10°/L).
Conclusions:
All MTX-Tris conjugates have reduced toxicity compared with MTX. Similar results were observed with cytotoxicity experiments (see above).
Distribution of MTX-Tris Conjugates in Mice
Introduction:
MTX is an effective oral treatment for a disease with an autoimmune component such as psoriasis and rheumatoid arthritis. However its long-term use requires ongoing liver assessment due to the risk of hepatic atrophy, necrosis and cirrhosis. MTX also induces gastrointestinal irritation, renal toxicity and abortion. We have demonstrated that MTX-Tris conjugates are biologically active but are less toxic in vitro and in vivo (see above). In addition, the distribution of radiolabelled MTX-Tris conjugates as well as MTX, administered topically, orally (p/0) and intravenously (i/v) have been examined in mice using liquid scintillation and whole body autoradiography. This was to determine if MTX-Tris conjugates (or their breakdown products) accumulate in organs of concern for MTX toxicity and if their excretion patterns varied from those of MTX. Pertinent results are summarised below.
Results: 1. Mice given ['“C}-MTX-y-GT, both i/v and orally, demonstrated a higher level of radioactivity excreted in the faeces, but similar amounts in the urine compared with animals given [“C}-MTX. The tissue distribution of ['*C] was similar, but at lower levels in mice given [*C)-MTX-y-GT. These findings suggest that MTX-y-GT has greater hepatic clearance than MTX. 2. Following topical application, radiolabel from MTX-y-GTP3 was detected in the skin epidermis for longer periods than MTX treated mice. This suggests that MTX- y-GTP3 is retained in the skin to a greater extent than MTX. In addition, radioactivity is present in the skin from mice given oral [**C}-MTX-y-GTP1 and : [*H]-MTX-y-GTP3. These findings may have important implications regarding their potential use as anti-psoriatic treatments. 3. Following oral administration, both radiolabelled MTX-y-GTP1 and MTX-y-GTP3 show significantly reduced levels of counts in organs of concern for MTX toxicity.
This suggests either decreased absorption or increased hepatic excretion (ie enterohepatic circulation). However once these conjugates enter the circulation (ie following i/v administration) they appear to accumulate in the liver, spleen and lung.
This offers the potential to targeting drugs to specific organs following their conjugation to fatty acyl groups via Tris. 4. Radiolabel from ["'C]JMTX is mainly excreted in the urine and to a lesser extent in the faeces. In contrast, when [*CIMTX-y-GTP1 and [“C]MTX-y-GTP3 are delivered i/v, radiolabel is mainly eliminated in the faeces via hepatic excretion, with : very low levels detested in the urine. ~~ a
Discussion:
MTX-Tris conjugates, when given orally, accumulate to a lesser extent than
MTX in organs of concern for MTX toxicity because they either have greater hepatic clearance (MTX-y-GT) or low levels of absorption in the formulations tested (MTX-y-
GTP1 and MTX-y-GTP3). The distribution patterns may partially explain the reduced toxic side effects seen with the conjugates (see Toxicity section above). Reduced cellular uptake and polyglutamylation is also likely to contribute (see Cytotoxicity
Section above). Whilst MTX-y-GTP1 and MTX-y-GTP3 may accumulate in the liver, lung and spleen when administered i/v, we have not assessed toxic side effects. However
Gm WO 00/34281 PCT/AU99/01073 ~ itis unlikely that these conjugates are polyglutamylated, which is the mechanism widely attributed to MTX toxicity.
Both MTX-y-GTP1 and MTX-y-GTP3 were found in the skin following oral delivery.
This may have implications for their potential use as a therapeutic for psoriasis. 5 .
Clinical trial of MTX-y-GTP3 as a topical treatment for psoriasis
Psoriasis is a skin condition that affects 1-2% of people of European origin. It is an inflammatory and epidermal hyperproliferative disorder of unknown aetiology with a poor prognosis.
MTX, when taken orally, is an effective treatment for moderate to severe psoriasis. However its use is associated with immediate gastrointestinal problems and long-term liver toxicity. Approximately 6 weeks of treatment are needed before a . clinical response.
It has been postulated that topically-applied MTX would provide drug at the affected site and have fewer side-effects. This has been trialed (Weinstein et al., 1989) but overall the results were not promising, perhaps due to poor skin retention. From our observations it was considered likely that MTX-y-GTP3 would have increased skin retention as well as the biological activities of MTX.
Preclinical studies
Preclinical studies indicated that topically-applied MTX-y-GTP3 had biological activity that may make it suitable for the treatment of psoriasis. It had equivalent or better activity to MTX in reducing UVB-induced epidermal hyperproliferation in hairless mice (Figure 3) and suppressed UVB-induced epidermal DNA synthesis (Figure 4) as determined by the method of Molek et al.(Brit J Derm(1983) 108:25-31). Intradermal injection of MTX-y-GTP2 was more effective than MTX in reducing the growth of B16 melanomas (USP 5,952,499). Distribution studies (above) show that topically-applied
MTX-y-GTP3 is retained in the epidermis of hairless mice for longer periods than MTX.
MTX-y-GTP3 administered topically or orally is less toxic to hairless mice than MTX (See above).
These positive pre-clinical results and the lack of a good animal model for psoriasis led to a proof-of-concept trial of topical MTX-y-GTP3 in humans.
Clinical study design
The Small Plaque Assay (SPA) assesses the anti-psoriatic potential of compounds over a two week time course. The assay simultaneously tests 6 compounds on a single plaque under occlusion. The position of the test compounds on each plaque was randomised to eliminate evaluation bias and any drug interaction effects. Eleven patients were studied.
Treatments: 0.5% MTX-y-GTP3 solution (test formulation) 1.0% MTX-y-GTP3 solution (test formulation)
MTX-y-GTP3 vehicle (negative control) 0.5% MTX solution (reference formulation)
MTX vehicle (negative control) 0.05% betamethasone valerate (positive control) (All concentrations of MTX-y-GTP3 solutions are with respect to their MTX content).
Schedule
Day ....treatment Assessment 0 2% salicylic acid clinical & histology 1 drugs applied 3 drugs applied 6 drugs applied 8 drugs applied clinical 10 drugs applied 13 drugs applied clinical & histology 29 clinical 15 } Parameters TT
Approximately 6 weeks of oral MTX treatment are needed before a clinical response is evident. Therefore it was unlikely that a clinical result would be seen with topical MTX-y-GTP3 in the two week duration of the SPA (restricted for ethical reasons). However, early histological changes consistent with psoriasis resolution would be expected with an active agent. Therefore, as well as clinical assessment, a range of histopathological and immunohistological markers were assessed as follows:
. ® (linical
Infiltration and Erythema on days 0, 8, 15 and 29. s Histopathology
Parakeratosis Inflammatory infiltrate
Granularity Acanthosis
Vascular changes Epidermal thickness
Papillomatosis e Immunohistology
Involucrin ICAM-1
Filaggrin Ki-67" keratinocytes : CD4 and CD83" T-cells
Patient Selection
Male of any ethnic group, 18 to 70 years of | Pustular psoriasis, erythrodermic psoriasis, age. Females of non-reproductive status inverse psoriasis and/or active psoriasis also allowed. arthritis.
Serious intercurrent illness or active
Chronic plaque type psoriasis vulgaris for at | infections requiring treatment, including least 6 months. hepatitis or AIDS. ] Known to be HIV positive.
Capable of understanding the purposes and | Known hypersensitivity to trial medication risks of the trial, giving the impression that | components. . she/he is willing to partake in all History of and/or present systemic assessments for the whole duration and has | malignancy. given written informed consent. Simultaneous participation in any other investigational drug trial or receiving
Required plaque characteristics: investigational drug 4 weeks prior to start ] e On trunk or extremities; not in a flexure | of trial. area. Received any systemic anti-psoriatic eo Areaatleast 5.5 x 8.3 cm. therapy 4 weeks prior to start of trial. » Homogeneous appearance (erythema Received any topical anti-psoriatic therapy and infiltration). for the plaque tested two weeks prior to e Severe erythema & infiltration start of trial.
Laboratory values that contra-indicate participation im tre tied. — — 7 —————
Any form of substance abuse, psychiatric disorder or condition which may invalidate communication with the investigator.
Known to have cirrhosis of the liver or other liver disease.
Patients taking medications which may ] interact with MTX.
Patients who have a calculated creatinine clearance < 30 ml/min,
Ye . WO 00/34281 PCT/AU99/01073
Results:
Clinical
The positive control, betamethasone, significantly improved the clinical appearance of test areas indicating that the trial methodology was preforming correctly.
Little or no change was observed in the MTX-y-GTP3 or MTX test spot areas over the two week period. This was not unexpected as the time course required for anti-psoriatic activity of oral MTX is 6 weeks. No serious side effects or local irritation were observed with any test compounds.
Histological
Statistically, betamethasone demonstrated anti-psoriatic activity in all parameters except hyperkeratosis and involucrin. : MTX-y-GTP3 treatment had positive effects on filaggrin expression (a marker of terminal epidermal differentiation), granularity (granular layer is absent or incomplete in psoriasis) and parakeratosis (imperfect formation of epidermal horn cells) in five out of eleven patients. Filaggrin.
Of all the immunobhistological markers examined, filaggrin proved to be the most powerful indicator of the action of the test drugs. Examination of filaggrin results within patients showed a correlation between response to betamethasone and response to MTX-y-GTP3 solution (Figure 5). MTX-y-GTP3 solution showed the best filaggrin response at a concentration of 0.5% while 1% MTX-y-GTP3 and 0.5% MTX gave approximately equivalent results. As a group, there were differences in filaggrin expression in the stratum granulosum with 0.5% MTX-y-
GTP3 solution compared to vehicle. There was a similar response to MTX (Figure 6). ¢ Granularity Parakeratosis Ratio.
The granularity to parakeratosis ratio was calculated to give an index of therapy — an increase in the ratio indicates a trend towards psoriasis resolution. Histopathological changes in granularity and parakeratosis consistent with early resolution of psoriasis were evident with 0.05% betamethasone valerate cream (10 out of 11 patients) and 1.0% MTX-y-GTP3 solution (5 out of 11 patients) — Figure 7 a) and b). Treatment with 0.5% MTX-y-GTP3 and MTX resulted in little response in granularity:parakeratosis ratio (1 & 2 patients respectively).
Clinical study conclusions
MTX-y-GTP3 demonstrated anti-psoriatic effects in a number of patients in comparison to its vehicle as judged by histopathology (granularity and parakeratosis) and the keratinocyte maturation marker, filaggrin. This, coupled with its relatively low toxicity compared to MTX makes it a potential therapeutic for the topical treatment of recalcitrant psoriasis.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described, The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (20)
1. A compound having the formula I: A M—[¥]—NH—C—CX,~O—R, B in which M is methotrexate or an analogue thereof: A=H, CX,-O-R; or halogen; B=H, CX>-O-R; or halogen; X is independently H or halogen; n is 0 or greater than or equal to I; . 10 Y is a linker group, and where n is greater than 1, each Y is the same or different; R1,Rz, and R; are the same or different and are either hydrogen, substituted or unsubstituted methyl, ethyl, a saturated or unsaturated fatty acyl group, ) with the proviso that when nis 0 or 1, and A is CH,-O-R; and/or B is CH,-O-R;, then Ry, R; and Rj are not selected from a fatty acyl group; with the proviso that when n is greater than or equal to 2, and A is CH;-O-R, and/or B is CH2-O-Rs, and at least one of R;, R; and R; is a fatty acyl group, then <[Y]a- 1s other than -(AA),- or -Y-(AA),.;-, where AA is an amino acid.
2. A compound according to claim 1 wherein M is attached via its y carboxyl group.
3. A compound according to claim 1 wherein Y is selected from the group consisting of: a) a compound having a carboxyl group and an amino group; b) a compound having an amino group and a sulphonic acid group; c) a compound having an hydroxyl group and a carboxyl group; d) a compound having an hydroxyl group and a sulfonic acid group; e) a compound having an hydroxyl group and a reactive halide group; f) a compound having a halide group and a carboxyl group; g) a compound having two reactive halide groups; h) a compound having an hydroxyl group and an aldehyde group; and i) an alkylene oxide.
4. A compound as claimed in any one of the preceding claims wherein -[Y],~ is - [AA},-, where the or each AA is an amino acid.
5. A compound according to any one of claim 4 wherein n is 1 and AA is glycine.
6 A compound according to claim 4 wherein n is 2 and AA is glycine.
7. A compound according to any one of the preceding claims wherein A and B are CH,OH and R isH.
8. Methotrexate-y-glycine Tris.
9. Methotrexate-y-glycine glycine Tris. :
10. A pharmaceutical composition including a compound according to any one of the preceding claims and a pharmaceutically acceptable carrier or diluent.
11. A pharmaceutical composition according to claim 10 wherein the composition is in a form suitable oral administration.
12. A pharmaceutical composition according to claim 10 wherein the composition is in a form suitable for parenteral administration.
13. A method of treatment of a disease with an autoimmune component or a cancer in a subject, the method including administration to the subject of an effective amount of oo a compound iii 4¢corddtte with uf furiuta I. = Ce —— I M=[Yl—NH=C=CX,0—R, B in which M is methotrexate or an analogue thereof: A=H, CX,-O-R; or halogen, B=H, CX,-O-R; or halogen; X is independently H or halogen; n is O or greater than or equal to 1;
St WO 00/34281 PCT/AU99/01073 Y is a linker group, and where n is greater than 1, each Y is the same or different; Ri,R;, and R; are the same or different and are either hydrogen, substituted or unsubstituted methyl, ethyl, a saturated or unsaturated fatty acyl group, with the proviso that when nis 0 or 1, and A is CH,-O-R, and/or B is CH;-0O-R;, then R,, R, and Rs are not selected from a fatty acyl group; with the proviso that when n is greater than or equal to 2, and A is CH,-O-R, and/or B is CH,-O-R;, and at least one of Ry, R; and Rj is a fatty acyl group, then -[Y]:- is other than -(AA),- or -Y-(AA), ;-, where AA is an amino acid.
14. A method according to claim 13 wherein M is attached via its y carboxyl group.
15. A method according to claim 13 or claim 14 wherein the treatment is of a diseasc . with an autoimmune component.
16. A method according to any one of claims 13 to 15 wherein the disease with an ; autoimmune component is selected from the group consisting of psoriasis, rheumatoid arthritis, inflammatory bowel disease and Crohn's disease.
17. A method according to claim 16 wherein the disease is psoriasis.
18. A method according to claim 16 wherein the disease is rheumatoid arthritis.
19. A method according to any one of claims 13 to 18 wherein the compound of formula I is administered by oral or parenteral administration. :
20. A method according to any one of claims 13 to 19 wherein the compound of formula 1 is methotrexate-y-glycine-Tris.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP7513A AUPP751398A0 (en) | 1998-12-04 | 1998-12-04 | Methotrexate derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104533B true ZA200104533B (en) | 2002-06-03 |
Family
ID=3811723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104533A ZA200104533B (en) | 1998-12-04 | 2001-06-01 | Methotrexate derivatives. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1135390A1 (en) |
JP (1) | JP2002531566A (en) |
KR (1) | KR20010081050A (en) |
CN (1) | CN1334815A (en) |
AU (1) | AUPP751398A0 (en) |
CA (1) | CA2353839A1 (en) |
NO (1) | NO20012720L (en) |
WO (1) | WO2000034281A1 (en) |
ZA (1) | ZA200104533B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1958632A1 (en) * | 2007-02-14 | 2008-08-20 | Dan Stoicescu | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases |
CN101926860A (en) * | 2010-05-07 | 2010-12-29 | 宁波立华制药有限公司 | Peony extract-methotrexate composition, preparation method thereof and use thereof |
CN110174363A (en) * | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501655A (en) * | 1993-08-02 | 1997-02-18 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | Therapeutic compound-fatty acid conjugate |
JPH11502509A (en) * | 1995-01-16 | 1999-03-02 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | Therapeutic compounds-fatty acid conjugates |
-
1998
- 1998-12-04 AU AUPP7513A patent/AUPP751398A0/en not_active Abandoned
-
1999
- 1999-12-03 JP JP2000586727A patent/JP2002531566A/en not_active Withdrawn
- 1999-12-03 EP EP99960710A patent/EP1135390A1/en not_active Withdrawn
- 1999-12-03 CA CA002353839A patent/CA2353839A1/en not_active Abandoned
- 1999-12-03 CN CN99815957A patent/CN1334815A/en active Pending
- 1999-12-03 WO PCT/AU1999/001073 patent/WO2000034281A1/en not_active Application Discontinuation
- 1999-12-03 KR KR1020017006889A patent/KR20010081050A/en not_active Application Discontinuation
-
2001
- 2001-06-01 NO NO20012720A patent/NO20012720L/en not_active Application Discontinuation
- 2001-06-01 ZA ZA200104533A patent/ZA200104533B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AUPP751398A0 (en) | 1999-01-07 |
CA2353839A1 (en) | 2000-06-15 |
WO2000034281A1 (en) | 2000-06-15 |
EP1135390A1 (en) | 2001-09-26 |
JP2002531566A (en) | 2002-09-24 |
NO20012720L (en) | 2001-07-31 |
NO20012720D0 (en) | 2001-06-01 |
CN1334815A (en) | 2002-02-06 |
KR20010081050A (en) | 2001-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6281376B1 (en) | Therapeutic compound—fatty acid conjugates | |
EP2818169A1 (en) | Conjugate of polyglycol and naloxone and pharmaceutical composition and use thereof | |
US6028071A (en) | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors | |
JP2002501512A (en) | A conjugate comprising a folate antagonist and a carrier | |
EP3867256A1 (en) | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | |
WO1998002163A9 (en) | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors | |
ES2868180T3 (en) | Pyrido-imidazo rifamycin derivatives as antibacterial agents | |
ZA200104533B (en) | Methotrexate derivatives. | |
Roth et al. | 2, 4-Diamino-5-benzylpyrimidines and analogs as antibacterial agents. 9. Lipophilic trimethoprim analogs as antigonococcal agents | |
EP0096870A1 (en) | Ester of metronidazole with N,N-dimethylglycine and acid addition salt thereof | |
Nair et al. | Folate analogs. 22. Synthesis and biological evaluation of two analogs of dihydrofolic acid possessing a 7, 8-dihydro-8-oxapterin ring system | |
Sigel et al. | Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase | |
AU1761500A (en) | Methotrexate derivatives | |
US20170260190A1 (en) | Substituted pyrimidine compounds and methods of use and manufacture | |
US8158764B2 (en) | Morphine derivatives | |
EP3299381B1 (en) | Water soluble rapamycin derivative | |
FI80699B (en) | FOR EXAMINATION OF THERAPEUTIC ANALYSIS OF 6-SUBSTITUERAD-5-PHENYLTETRAZOLE / 1,5-A // 1,2,4 / TRIAZOLE / 1,5-C / PYRIMIDINER. | |
Nair et al. | Folate analogs altered in the C9-N10 bridge region. 16. Synthesis and antifolate activity of 11-thiohomoaminopterin | |
CN101311167B (en) | 1-phenyl glyoxaline alkane -2,4-dione derivates and uses thereof | |
Lee et al. | The synthesis, characterization and biological testing of a novel class of mucosal permeation enhancers | |
EP0154173B1 (en) | Pteridine derivatives, an anticancer composition containing same and a process for the production of said derivatives | |
WO2016179011A1 (en) | Antifolate conjugates for treating inflammation | |
CN116514829A (en) | Water-soluble antitumor prodrug, and pharmaceutical composition and application thereof | |
JPH0769883A (en) | Aromatase inhibitor | |
AU709252B2 (en) | Therapeutic compound - fatty acid conjugates |